1.
Turnšek N, Devjak R, Edelbaher N, Osrajnik I, Unk M, Vidovič D, Jerič T, Janžič U. Real-world outcomes, treatment patterns and T790M testing rates in Non-Small Cell Lung Cancer patients treated with first-line first- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors from the Slovenian cohort of the REFLECT: Outcomes and treatments of EGFR-mutated NSCLC patients from Slovenia. RO [Internet]. 2022 Sep. 8 [cited 2022 Nov. 30];56(3):371-9. Available from: https://radioloncol.com/index.php/ro/article/view/3840